Cargando…
Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods. We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated....
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176715/ https://www.ncbi.nlm.nih.gov/pubmed/21752873 http://dx.doi.org/10.1093/rheumatology/ker221 |
_version_ | 1782212241655857152 |
---|---|
author | Takeuchi, Tsutomu Tanaka, Yoshiya Amano, Koichi Hoshi, Daisuke Nawata, Masao Nagasawa, Hayato Sato, Eri Saito, Kazuyoshi Kaneko, Yuko Fukuyo, Shunsuke Kurasawa, Takahiko Hanami, Kentaro Kameda, Hideto Yamanaka, Hisashi |
author_facet | Takeuchi, Tsutomu Tanaka, Yoshiya Amano, Koichi Hoshi, Daisuke Nawata, Masao Nagasawa, Hayato Sato, Eri Saito, Kazuyoshi Kaneko, Yuko Fukuyo, Shunsuke Kurasawa, Takahiko Hanami, Kentaro Kameda, Hideto Yamanaka, Hisashi |
author_sort | Takeuchi, Tsutomu |
collection | PubMed |
description | Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods. We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated. Results. Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% of the patients had been treated previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7%, radiographic non-progression in 62.8% and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to tocilizumab discontinuation were observed in 15.5% of patients, the most frequent adverse drug reaction being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable for remission of all three types—clinical, radiographic and functional—at Week 52 of tocilizumab treatment. Conclusions. In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed safety findings are required, this study provides valuable real-world findings on the management of RA with tocilizumab. |
format | Online Article Text |
id | pubmed-3176715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31767152011-09-20 Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study Takeuchi, Tsutomu Tanaka, Yoshiya Amano, Koichi Hoshi, Daisuke Nawata, Masao Nagasawa, Hayato Sato, Eri Saito, Kazuyoshi Kaneko, Yuko Fukuyo, Shunsuke Kurasawa, Takahiko Hanami, Kentaro Kameda, Hideto Yamanaka, Hisashi Rheumatology (Oxford) Clinical Science Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods. We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated. Results. Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% of the patients had been treated previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7%, radiographic non-progression in 62.8% and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to tocilizumab discontinuation were observed in 15.5% of patients, the most frequent adverse drug reaction being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable for remission of all three types—clinical, radiographic and functional—at Week 52 of tocilizumab treatment. Conclusions. In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed safety findings are required, this study provides valuable real-world findings on the management of RA with tocilizumab. Oxford University Press 2011-10 2011-07-13 /pmc/articles/PMC3176715/ /pubmed/21752873 http://dx.doi.org/10.1093/rheumatology/ker221 Text en © The Author 2011. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Science Takeuchi, Tsutomu Tanaka, Yoshiya Amano, Koichi Hoshi, Daisuke Nawata, Masao Nagasawa, Hayato Sato, Eri Saito, Kazuyoshi Kaneko, Yuko Fukuyo, Shunsuke Kurasawa, Takahiko Hanami, Kentaro Kameda, Hideto Yamanaka, Hisashi Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study |
title | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study |
title_full | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study |
title_fullStr | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study |
title_full_unstemmed | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study |
title_short | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study |
title_sort | clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—reaction 52-week study |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176715/ https://www.ncbi.nlm.nih.gov/pubmed/21752873 http://dx.doi.org/10.1093/rheumatology/ker221 |
work_keys_str_mv | AT takeuchitsutomu clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT tanakayoshiya clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT amanokoichi clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT hoshidaisuke clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT nawatamasao clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT nagasawahayato clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT satoeri clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT saitokazuyoshi clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT kanekoyuko clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT fukuyoshunsuke clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT kurasawatakahiko clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT hanamikentaro clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT kamedahideto clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy AT yamanakahisashi clinicalradiographicandfunctionaleffectivenessoftocilizumabforrheumatoidarthritispatientsreaction52weekstudy |